JAK1 (Janus Kinase 1)

Taken together, ZDHHC9 promotes GC progression by regulating the conversion of STAT1 S-palmitoylation and phosphorylation, providing potential therapeutic targets for GC treatment.

Collectively, the interference of DPPE-PEG with iNKT cells activation evidenced by reduced CD1d expression and IL-13 cytokine, with subsequently retarded activation of JAK1/STAT6 inflammatory signaling and preserved intestinal mucosa could, at least partly, contribute to impeding the progression of colitis. These findings reinforce our suggestion that DPPE-PEG could be an effective and promising candidate for retarding the advancement of ulcerative colitis.

P1, N=10, Completed, Zhejiang University | Recruiting --> Completed | N=16 --> 10 | Trial completion date: Aug 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025

Pyroptosis is a newly defined form of programmed cell death characterized by plasma membrane perforation, release of cellular contents, and a robust inflammatory response, thereby sensitizing tumors to existing anticancer therapies. Furthermore, the combination of SAQ with sorafenib, a first-line therapeutic agent for HCC, exhibited synergistic antitumor activity both in vitro and in the nude mouse model. These findings not only identify SAQ as a novel pyroptosis-inducer, but also clarify the critical role of the OTUD5-JAK1-GSDME axis in resisting pyroptosis, which may further provide experimental evidence and potential new strategies for treating HCC.

LC-derived exosomal circ_001895 stimulated M2 macrophage polarization to promote LC metastasis via the miR-20a-5p/JAK1/STAT3 axis. These findings suggest that exosomal circ_001895 may serve as a potential biomarker and therapeutic target in lung cancer.

In contrast, HEXIM1+CAF-C1 may act as an independent risk factor for poor prognosis in CRC. Our findings enhance understanding of immune escape mechanisms in CRC, show how novel subtypes affect prognosis, and offer insights for new diagnostic and treatment strategies.

STE reprograms TAMs via the JAK1/STAT1 axis and exhibits robust antitumor activity, underscoring its promise as a natural, macrophage-targeted immunotherapeutic that warrants further investigation for integration into cancer treatment strategies.

Quercetin mitigates breast cancer-diabetes progression by targeting hub genes involved in IL6/JAK1/STAT3/MMP9 signaling pathway and metabolic dysregulation. This study provides a mechanistic foundation for quercetin as a precision therapeutic target in breast cancer with diabetes comorbidity.

Thimerosal exerts dual antitumor roles by direct JAK1/STAT3 inhibition and immune modulation via CD8+ T cell recruitment. It represents a promising repurposed drug and immunotherapeutic adjuvant for CRC and melanoma.

In line with this finding, both JAK1 knockout and kinase inhibition with abrocitinib prevented subsequent formation of radiation-induced micronuclei. Targeting the mitotic kinesin KIF18A with the small molecule sovilnesib exacerbated mitotic stress and enhanced the efficacy of radiation. These studies establish KIF18A inhibition as a strategy to counteract the protective G2/M cell cycle arrest induced by DNA damage and to thus enhance tumor cell sensitivity to radiation therapy.

RAB10 interacts with IFNAR1 to suppress the JAK1/STAT1 signaling pathway, thereby inhibiting M1 polarization and promoting M2 polarization of macrophages. Inhibition of RAB10, especially in combination with PD-L1 blockade, offers a promising strategy to enhance anti-tumor immunity and overcome therapeutic resistance in breast cancer.

It also inhibited the JAK/STAT3 signaling pathway, promoted apoptosis, downregulated Ki-67 expression, and attenuated EMT progression. CDN inhibits CRC progression and induces apoptosis by targeting the JAK/STAT3/EMT signaling axis, suggesting that CDN is a promising therapeutic agent for CRC.